Q-omics provides the consensus-scored SCN10A profile across patient tissues and cancer cell-line models. SCN10A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SCN10A is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, SCN10A mutation status shows 7,187 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight ACC, KIRC, and UCEC as cancer lineages where SCN10A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCN10A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCN10A survival associations across molecular data types. SCN10A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCN10A RNA expression–survival associations across cancer types. High SCN10A expression shows unfavorable associations in ACC and BRCA, but favorable associations in KIRP, KIRC, CESC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify ACC as the clearest survival context for SCN10A RNA expression.
This table summarizes SCN10A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SCN10A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCN10A shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, KIRP, PRAD and THCA. The KIRC box plot shows higher SCN10A RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p < 0.001).
This table shows molecular features associated with SCN10A in patient tissues and cancer cell lines. In patient samples, SCN10A shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, SCN10A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
